1-9 of 9
Olivier Rixe
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A First-in-Human Phase I Study of BXQ-350, a First-in-Class Sphingolipid Metabolism Regulator, in Patients with Advanced/Recurrent Solid Tumors or High-Grade Gliomas

Olivier Rixe, John L. Villano, Robert Wesolowski, Anne M. Noonan, Vinay K. Puduvalli, Trisha M. Wise-Draper, Richard Curry, III, Emrullah Yilmaz, Charlie Cruze, Besim Ogretmen, Gilles Tapolsky, Ray Takigiku
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (22): 5053–5060.
https://doi.org/10.1158/1078-0432.CCR-24-1721
Published: 15 November 2024
View articletitled, A First-in-Human Phase I Study of BXQ-350, a First-in-Class Sphingolipid Metabolism Regulator, in Patients with Advanced/Recurrent Solid Tumors or High-Grade Gliomas
Open the PDF for A First-in-Human Phase I Study of BXQ-350, a First-in-Class Sphingolipid Metabolism Regulator, in Patients with Advanced/Recurrent Solid Tumors or High-Grade Gliomas in another window
Includes: Supplementary data
Journal Articles

Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors

Diwakar Davar, Roberta Zappasodi, Hong Wang, Girish S. Naik, Takami Sato, Todd Bauer, David Bajor, Olivier Rixe, Walter Newman, Jingjing Qi, Aliya Holland, Phillip Wong, Lianna Sifferlen, Diane Piper, Cynthia A. Sirard, Taha Merghoub, Jedd D. Wolchok, Jason J. Luke
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (18): 3990–4002.
https://doi.org/10.1158/1078-0432.CCR-22-0339
Published: 15 September 2022
View articletitled, Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors
Open the PDF for Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Mogamulizumab in Combination with Nivolumab in a Phase I/II Study of Patients with Locally Advanced or Metastatic Solid Tumors

David S. Hong, Olivier Rixe, Vi K. Chiu, Patrick M. Forde, Tomislav Dragovich, Yanyan Lou, Asha Nayak-Kapoor, Rom Leidner, James N. Atkins, Agron Collaku, Floyd E. Fox, Margaret A. Marshall, Anthony J. Olszanski
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (3): 479–488.
https://doi.org/10.1158/1078-0432.CCR-21-2781
Published: 01 February 2022
View articletitled, Mogamulizumab in Combination with Nivolumab in a Phase I/II Study of Patients with Locally Advanced or Metastatic Solid Tumors
Open the PDF for Mogamulizumab in Combination with Nivolumab in a Phase I/II Study of Patients with Locally Advanced or Metastatic Solid Tumors in another window
Journal Articles

High-Dose Sirolimus and Immune-Selective Pentostatin plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-versus-Tumor Responses

Miriam E. Mossoba, David C. Halverson, Roger Kurlander, Bazetta Blacklock Schuver, Ashley Carpenter, Brenna Hansen, Seth M. Steinberg, Syed Abbas Ali, Nishant Tageja, Frances T. Hakim, Juan Gea-Banacloche, Claude Sportes, Nancy M. Hardy, Dennis D. Hickstein, Steven Z. Pavletic, Hanh Khuu, Marianna Sabatini, David Stroncek, Bruce L. Levine, Carl H. June, Jacopo Mariotti, Olivier Rixe, Antonio Tito Fojo, Michael R. Bishop, Ronald E. Gress, Daniel H. Fowler
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (19): 4312–4320.
https://doi.org/10.1158/1078-0432.CCR-15-0340
Published: 30 September 2015
View articletitled, High-Dose Sirolimus and Immune-Selective Pentostatin plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-versus-Tumor Responses
Open the PDF for High-Dose Sirolimus and Immune-Selective Pentostatin plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-versus-Tumor Responses in another window
Journal Articles

Multicenter, Phase II Study of Axitinib, a Selective Second-Generation Inhibitor of Vascular Endothelial Growth Factor Receptors 1, 2, and 3, in Patients with Metastatic Melanoma

John Fruehauf, Jose Lutzky, David McDermott, Charles K. Brown, Jean-Baptiste Meric, Brad Rosbrook, David R. Shalinsky, Katherine F. Liau, Andreas G. Niethammer, Sinil Kim, Olivier Rixe
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (23): 7462–7469.
https://doi.org/10.1158/1078-0432.CCR-11-0534
Published: 30 November 2011
View articletitled, Multicenter, Phase II Study of Axitinib, a Selective Second-Generation Inhibitor of Vascular Endothelial Growth Factor Receptors 1, 2, and 3, in Patients with Metastatic Melanoma
Open the PDF for Multicenter, Phase II Study of Axitinib, a Selective Second-Generation Inhibitor of Vascular Endothelial Growth Factor Receptors 1, 2, and 3, in Patients with Metastatic Melanoma in another window
Journal Articles

Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors

Brian I. Rini, Joan H. Schiller, John P. Fruehauf, Ezra E.W. Cohen, Jamal C. Tarazi, Brad Rosbrook, Angel H. Bair, Alejandro D. Ricart, Anthony J. Olszanski, Kristen J. Letrent, Sinil Kim, Olivier Rixe
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (11): 3841–3849.
https://doi.org/10.1158/1078-0432.CCR-10-2806
Published: 01 June 2011
View articletitled, Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors
Open the PDF for Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors in another window
Journal Articles

Validation of Analytic Methods for Biomarkers Used in Drug Development

Cindy H. Chau, Olivier Rixe, Howard McLeod, William D. Figg
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (19): 5967–5976.
https://doi.org/10.1158/1078-0432.CCR-07-4535
Published: 30 September 2008
View articletitled, Validation of Analytic Methods for Biomarkers Used in Drug Development
Open the PDF for Validation of Analytic Methods for Biomarkers Used in Drug Development in another window
Journal Articles

Is Cell Death a Critical End Point for Anticancer Therapies or Is Cytostasis Sufficient?

Olivier Rixe, Tito Fojo
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (24): 7280–7287.
https://doi.org/10.1158/1078-0432.CCR-07-2141
Published: 19 December 2007
View articletitled, Is Cell Death a Critical End Point for Anticancer Therapies or Is Cytostasis Sufficient?
Open the PDF for Is Cell Death a Critical End Point for Anticancer Therapies or Is Cytostasis Sufficient? in another window
Journal Articles

A Phase I and Pharmacokinetic Study of the Novel Aza-Anthracenedione Compound BBR 2778 in Patients with Advanced Solid Malignancies

Sandrine Faivre, Eric Raymond, Valérie Boige, Michel Gatineau, Xavier Buthaut, Olivier Rixe, Alberto Bernareggi, Gabriella Camboni, Jean-Pierre Armand
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (1): 43–50.
Published: 01 January 2001
View articletitled, A Phase I and Pharmacokinetic Study of the Novel Aza-Anthracenedione Compound BBR 2778 in Patients with Advanced Solid Malignancies
Open the PDF for A Phase I and Pharmacokinetic Study of the Novel Aza-Anthracenedione Compound BBR 2778 in Patients with Advanced Solid Malignancies in another window